Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers. Ynicl (2018), Abstract INTRODUCTION: In vivo clinical, anatomical and metabolic differences between posterior cortical atrophy (PCA) patients presenting with different Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers profiles are still unknown. METHODS: Twenty-seven PCA patients underwent CSF examination and were classified as 1) PCA with a typical CSF AD profile (PCA-tAD; abnormal amyloid and Ttau/P-tau biomarkers, n=13); 2) PCA with an atypical AD CSF profile (PCA-aAD; abnormal amyloid biomarker only, n=9); and 3) PCA not associated with AD (PCA-nonAD; normal biomarkers, n=5). All patients underwent clinical and cognitive assessment, structural MRI, and a subset of them underwent brain 18 F-FDG PET. RESULTS: All patients' groups showed a common pattern of posterior GM atrophy and hypometabolism typical of PCA, as well as equivalent demographics and clinical/cognitive profiles. PCA-tAD patients showed a group-specific pattern of hypometabolism in the left fusiform gyrus and inferior temporal gyrus. PCA-aAD did not present a group-specific atrophy pattern. Finally, group-specific gray matter atrophy in the right dorsolateral prefrontal cortex, left caudate nucleus and right medial temporal regions and hypometabolism in the right supplementary motor area and paracentral lobule were observed in PCA-nonAD patients. CONCLUSION: Our findings suggest that both PCA-tAD and PCA-aAD patients are on the AD continuum, in agreement with the recently suggested A/T/N model. Furthermore, in PCA, the underlying pathology have an impact at least on the anatomo-functional presentation. Brain damage observed in PCA-tAD and PCA-aAD was mostly consistent ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T 3
Introduction
Posterior cortical atrophy (PCA) is a rare neurodegenerative syndrome mainly characterized by progressive high-level visual and visuo-motor impairments, in the absence of ophthalmologic impairment (Benson et al., 1988; Migliaccio et al., 2012a) .
The most frequent clinical manifestations include elements of Balint's and Gerstmann's syndromes, visual agnosia, alexia, apraxia and environmental disorientation (McMonagle et al., 2006) . PCA is associated with bilateral parietal, occipital and posterior temporal gray matter (GM) atrophy (Whitwell et al., 2007) and hypometabolism (Kas et al., 2011) , and it has been shown that brain damage remains posterior even in the late stages of the disease (Kas et al., 2011) .
Previous clinico-biological (Beaufils et al., 2013; Beaufils et al., 2014; Coppi et al., 2014; de Souza et al., 2011a; de Souza et al., 2011b; Seguin et al., 2011) and clinicopathologic (Renner et al., 2004; Tang-Wai et al., 2004) series have shown that the most frequent neuropathological substrate of PCA is Alzheimer's disease (AD) pathology. For this reason, PCA is considered an atypical variant of AD, in patients with early age at onset (Benson et al., 1988; Migliaccio et al., 2009; Panegyres et al., 2017) . The AD cerebrospinal fluid (CSF) biomarkers' profile is characterized by high levels of total tau (T-tau) and phosphorylated tau at threonine 181 (P-tau), combined with a reduction of amyloid beta 1-42 (Aβ 1-42 ), and represents the most sensitive and specific tool to diagnose AD pathology in vivo (de Souza et al., 2011b; Dubois et al., 2014) . However, some patients can present an atypical AD CSF profile (i.e. only decreased Aβ 1-42 or only increased tau) (Beaufils et al., 2013; Beaufils et al., 2014; Coppi et al., 2014; Seguin et al., 2011) or a non-AD CSF profile (Renner et al., 2004; Seguin et al., 2011; Tang-Wai et , 2004) . This is in the vein of the suggested A/T/N model of AD (Jack et al., 2018; Jack et al., 2016 ), a descriptive system for categorizing multidomain biomarker findings at the individual person level. This model considers three elements: the value of βamyloid biomarker (amyloid PET or CSF Aβ 1-42 , A); the value of tau biomarker (CSF Ptau, or tau PET, T); and biomarkers of neurodegeneration or neuronal injury ([18F]fluorodeoxyglucose-PET, structural MRI, or CSF T-tau, N). With the movement of the amnestic AD research field towards the A/T/N model, it is essential for clinically atypical AD patients (such as PCA patients) to also be characterized in the perspective of this model.
In this study, we aimed to investigate GM density, brain metabolism and clinical/cognitive profiles in a large sample of 27 PCA patients according to their AD CSF biomarkers profiles. Despite the growing number of observations, in vivo clinicoanatomical differences between PCA patients presenting with these different CSF biomarkers profiles are still unknown. We hypothesized that PCA patients with different AD CSF profiles have different patterns of brain damage and clinical/cognitive presentation.
Material and methods

Subjects
Twenty-seven PCA patients, 30 age-matched healthy subjects with available magnetic resonance imaging (MRI) scan and 17 age-matched healthy subjects with available positron emission tomography (PET) scan (CTRL, without history of neurological or psychiatric disease) participated in this study. Clinical and cognitive data
were acquired at the Centre National de Référence "Démences Rares", located at the "Institut de la mémoire et de la maladie d'Alzheimer" (IM2A), in the Pitié-Salpêtrière Hospital, Paris. Clinical diagnosis was based on a multi-disciplinary evaluation including clinical history and neurological examination, caregiver interview, and neuropsychological battery. Neurological assessment and diagnosis were performed by trained clinicians (R.M., L.L., A.M., S.E. and B.D.) with expertise in the field of dementia. Medical records of patients clinically diagnosed with PCA were reviewed by a neurologist (R.M.) and a neuropsychologist (M.M.) to ensure they met PCA diagnostic criteria. Diagnosis of PCA was made based on: 1) presentation with progressive visual or visuospatial impairment in the absence of ophthalmologic impairment; 2) evidence of complex visual disorder on examination: elements of Balint's and Gerstmann's syndrome, visual agnosia, alexia, apraxia, or environmental disorientation; 3)
proportionately less memory loss (Alladi et al., 2007; McMonagle et al., 2006) . To meet criteria, patients were required to present with early complaints of visual and visuospatial impairment in the absence of major memory complaints. Exclusion criteria for this study included history of other neurological or psychiatric diseases, ophthalmologic disease, extrapyramidal symptoms or signs, hallucinations, cognitive fluctuations, lefthandedness, rapidly evolving dementia syndromes, or substantial MRI T2 white matter hyperintensities in the occipito-parietal regions.
PCA patients were then divided in groups based on AD CSF biomarkers. The AD CSF signature usually combines low Aβ 1-42 and high T-tau or P-tau concentrations (Dubois et al., 2014) . In this study, Aβ 1-42, T-tau and P-tau were measured for each patient [for procedure see (Teichmann et al., 2013) ]. Two ratios obtained in a previous study
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T 7 from our department were used as the main inclusion criterion to determine if a patient presented the AD CSF signature, namely a T-tau/Aβ 1-42 cut-off of <1.23 pg/ml and a Ptau/Aβ 1-42 cut-off of <0.211 pg/ml (de Souza et al., 2011b) . These ratios have respective sensitivities of 95% and 91.7%, and respective specificities of 84.8% and 89.1% in distinguishing AD from other neurodegenerative dementias involving pathological processes distinct from AD. In addition to ratios, individual biomarkers levels were also considered for Aβ 1-42 (cut-off normal >500 pg/ml), T-tau (normal <450 pg/ml) and P-tau (normal <60 pg/ml) (Baldacci et al., 2017) .
Patients with typical CSF AD profile (PCA-tAD) were defined as follow: at least one pathological ratio, and low Aβ 1-42 combined with higher T-tau and/or P-tau. Patients presenting with an isolated reduction of Aβ 1-42 were defined as having an atypical CSF AD profile (PCA-aAD) (Seguin et al., 2011) , in agreement with the fact that isolated Aβ 1-42 reduction may indicate an amyloidogenic process (McKhann et al., 2011) . Patients who did not present any element of the CSF AD profile were classified as PCA-nonAD. The study was approved by the local committee on human research. All subjects provided written informed consent before participating.
Clinical/cognitive assessment
All patients underwent a neuropsychological screening battery including a global cognitive assessment with the Mini-Mental State Examination (MMSE) (Folstein et al., 1975) as well as an assessment of "frontal" brain functions with the Frontal Assessment Battery (FAB) (Dubois et al., 2000) , backwards digit and visual span (Wechsler, 1981) , and word generation tasks for category and letter fluency (Kremin et al., 1999) . A detailed exploration of "posterior" brain functions, through a battery specifically conceived for PCA patients which was previously described (Migliaccio et al., 2016) , was also administered. This battery was designed to investigate more "dorsal" deficits such as elements of Balint's and Gerstmann's syndromes, motor apraxia, ideomotor apraxia and visual neglect, as well as more "ventral" deficits such as alexia and visual agnosia. Patients were classified as impaired or not impaired on these symptoms and rates of subjects impaired in each group (PCA-tAD, PCA-aAD and PCA-nonAD) were compared with Fisher's exact test of independence (p ≤ .05) and effect sizes were calculated (Cramer's V).
Magnetic resonance imaging (MRI)
2.3.1. MRI acquisition. PCA patients, as well as a group of 30 age-and gendermatched healthy subjects (CTRL, men/women: 14/16; mean age = 61.5; standard deviation = 8.4; age range = 45-79), underwent the MRI protocol. Brain MRI were acquired with a 3T system (Siemens, Erlangen, Germany) at the Center for Magnetic Resonance Research (CENIR), Brain and Spine Institute (ICM), Paris. A high-resolution structural volume was acquired using a T1-weighted 3D magnetization prepared rapid gradient echo (MPRAGE) sequence (160 sagittal images; thickness 1 mm; FOV 256×256 mm 2 ; matrix size 256×256). Eight PCA patients (two PCA-tAD, four PCA-aAD and two PCA-nonAD) were scanned with compatible parameters but on a different MRI machine.
The type of MRI machine was therefore added as a control covariate in our statistical analyses.
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Affine registered tissue segments were used to create a custom template using the DARTEL (diffeomorphic anatomical registration using exponentiated lie algebra) approach (Ashburner, 2007) . For each participant, the flow fields were calculated during a template creation, which described the transformation from each native GM image to the template. These were then applied to each participant's GM image. The VBM analysis was based on modulated GM images, where the GM value for each voxel was multiplied by the Jacobian determinant derived from spatial normalization to preserve the total amount of GM from the original images (Ashburner and Friston, 2000) . The resulting modulated and normalized images were then smoothed with a Gaussian kernel of 8 mm FWHM.
VBM analyses.
The VBM analyses were performed on smoothed GM images. First, GM maps were compared between all PCA patients and controls using an ANOVA model adjusting for subject's age, gender, MRI machine and total intracranial volume.
Groups were entered separately in the statistical model in the following order: CTRL, PCA-tAD, PCA-aAD and PCA-nonAD. The following sets of linear contrasts were set in order to identify differences in GM volume in: 1) each PCA group vs. healthy PCA-tAD and PCA-aAD [0 1 1 -2];).
A first analysis was performed with the aim of investigating regions of common atrophy across PCA groups in comparison to CTRL (the results of contrast 2 were inclusively masked by all contrasts of set 1). This inclusive masking procedure limits the main effect contrast to regions that are present in each PCA group vs. CTRL contrast. A second analysis was performed in order to identify GM atrophy in each PCA group vs.
CTRL (contrast set 1). A third analysis was performed with the aim of investigating regions of atrophy in comparison to CTRL that are specific to each PCA group (the relevant contrast from contrast 1 (e.g., PCA-tAD vs. CTRL) were inclusively masked by the appropriate contrast from set 3 (e.g., PCA-tAD vs. PCA-atAD and PCA-nonAD). A significance threshold of p ≤ 0.05 corrected for multiple comparisons (family-wise error) was used for the second analysis and of p ≤ 0.001 uncorrected for the first and third analyses. To decrease the risk of false positive results, clusters of <20 voxels were not considered.
Positron emission tomography (PET)
2.4.1. PET acquisition. A subset of eight PCA patients (five PCA-tAD and three PCA-nonAD) as a well as a group of 17 age-and gender-matched healthy subjects (CTRL) underwent the PET protocol (Male/Female: 8/9; mean age = 63.2; standard deviation = 6.6; age range = 54-76). Brain 18 F-FDG PET scans were acquired 30 minutes after injection of 2 MBq/kg of 2-deoxy-2-( 18 F)fluoro-D-glucose. All acquisitions were performed in a single session on a Philips Gemini GXL scanner and consisted of 3 x 5 minutes' frames with a voxel size of 2 x 2 x 2 mm³. Images were then reconstructed using
iterative LOR-RAMLA algorithm. Lastly, frames were realigned, summed and qualitychecked.
2.4.2. PET pre-processing. All images were normalized to MNI space with a standard 18 F-FDG PET template using SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) and smoothed with a Gaussian kernel of 12 mm FWHM. Parametric PET images were then created for each subject, by dividing each voxel with the mean activity extracted from a reference region. For this study, we used the pons region available on the pickatlas toolbox (http://www.nitrc.org/projects/wfu_pickatlas/).
PET analyses.
The contrasts used for the VBM analyses were replicated with the same parameters for the PET analyses (section 2.3.3).
Results
Demographic and CSF data
Out of the 27 PCA patients in this study, 13 patients were classified as PCA-tAD (48%), nine as PCA-aAD (33%) and five patients as PCA-nonAD (19%). Demographics and CSF data of patients are presented in Table 1 . No differences were found in terms of age, disease duration and global cognition (as assessed with MMSE) between patients' groups.
Clinical and cognitive data
Clinical and cognitive characteristics of PCA-tAD, PCA-aAD and PCA-nonAD patients are presented in Table 1 . No significant difference was observed between groups of patients. However, meaningful effect sizes were found for several measures including (table 1) , which suggests a tendency towards statistical significance. Overall, PCA patients presented mild-to-moderate global cognitive impairment as well as typical dorsal and ventral symptoms that are characteristic of PCA. Both verbal and visuospatial working memory was impaired, while phonemic and categorical verbal fluency remained in the normal range. In terms of hypometabolism, the analyses on a subset of patients showed that PCA-tAD patients presented a specific pattern of hypometabolism in the left inferior temporal gyrus (x = -44, y = -14; z = -36; t=8.28; p ≤ .001 uncorrected but also significant at p ≤ .05 FWE corrected; figure 2B ). PCA-nonAD patients presented a specific pattern of hypometabolism including the right supplementary motor area and the right paracentral lobule (p ≤ .001 uncorrected; table 3 and figure 2B) . (Cohen, 1988) ]. Meaningful values are in bold.
ACCEPTED MANUSCRIPT
A 
Discussion
The present study reports, for the first time, a detailed exploration of a large group of patients on the PCA spectrum. We compared brain atrophy, brain hypometabolism and clinical/cognitive profiles in PCA patients according to their AD CSF biomarkers profiles.
As expected, we found that PCA was most frequently associated with AD pathology (81%), in agreement with previous in vivo (Beaufils et al., 2013; Beaufils et al., 2014; Coppi et al., 2014; de Souza et al., 2011a; de Souza et al., 2011b; Seguin et al., 2011) and post-mortem (Renner et al., 2004; Tang-Wai et al., 2004) studies. More precisely, forty-eight percent presented the typical AD CSF profile (PCA-tAD; abnormal Aβ 1-42 and T-tau/P-Tau biomarkers), and thirty-three percent presented the atypical AD CSF profile (PCA-aAD; isolated Aβ 1-42 decrease). The isolated Aβ 1-42 decrease is thought to be consistent with AD pathology, although it might be less specific than the typical AD CSF profile (Beaufils et al., 2013; Beaufils et al., 2014; Coppi et al., 2014; Seguin et al., 2011) . According to the A/T/N model (Jack et al., 2018; Jack et al., 2016) , both A+T+ N+ (PCA-tAD) and A+T-N-(PCA-aAD) patients are on the AD continuum, but are differentially labelled as "Alzheimer's disease" and "Alzheimer's pathologic change".
Within this framework, the Aβ 1-42 decrease means an early upstream pathophysiological process, whereas CSF T-tau level, for example, can be considered as a biomarker of downstream pathophysiological processes .
Nineteen percent presented a non-AD CSF profile, indicating that AD is not the underlying pathological substrate in these PCA cases. However, this CSF profile does not allow for the precise identification of the pathology. Non-AD pathologies such as CBD,
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A N U S C R I P T 24 DLB, and Creutzfeldt-Jakob disease have been described as possible in PCA (Renner et al., 2004; Tang-Wai et al., 2004) . Creutzfeldt-Jakob disease is associated with a very rapid disease progression and can therefore be ruled out in the presented PCA-nonAD cases, leaving CBD and DLB as the most plausible causes. In our study, we did not detect extrapyramidal symptoms, cognitive fluctuations or visual hallucinations in PCA-nonAD patients at symptom onset or at the time of neuroimaging acquisition. However, all patients from that group who afterwards underwent SPECT dopamine transporter imaging presented a nigrostriatal dopaminergic denervation. These findings provide support to underlying CBD or DLB (McCleery et al., 2015; Mille et al., 2016) in these patients, which can both present without clear and early motor manifestations (Bonner et al., 2003; Lee et al., 2011; Sakurai and Nakashima, 2017) . In these cases, a longitudinal follow-up is essential to assess if over time, they will develop CBD or DLB features.
Interestingly, out of five PCA-nonAD patients, only two of them had developed such features two to three years after their inclusion in the present study. One patient had , 2007) . In contrast, when we investigated the specificities of each subgroup, PCA-nonAD patients presented specific atrophy in the left caudate nucleus, right dorsolateral prefrontal cortex and anterior medial temporal regions, and groupspecific hypometabolism in the right supplementary motor area and paracentral lobule.
These areas are not typically reported in PCA (Kas et al., 2011; Migliaccio et al., 2016; Whitwell et al., 2007) . This might be due to the fact that PCA-nonAD patients are rare (Seguin et al., 2011) . Given that rarity, no previous study has investigated differences between PCA subgroups based on biological characterization, but they are rather included in general PCA groups for analyses. Interestingly, the regions in which grey matter and metabolism changes have been observed in PCA-nonAD patients highly overlap with regions affected in CBD and DLB, with a strong hemispheric lateralization (Lee et al., 2011; Su et al., 2015; Whitwell et al., 2017; Zhong et al., 2014) . This provides additional support for underlying CBD and DLB pathology in our PCA-nonAD patients.
Indeed, independently of the clinical presentation, the core regions affected in patients with CBD are the dorsal prefrontal cortex, the supplementary motor area, the perirolandic cortex and the striatum (Lee et al., 2011) with an asymmetry often reported between the hemispheres. In DLB patients, atrophy and hypometabolism in frontal, caudate nucleus and anterior temporal regions was previously described in comparison to both normal subjects (Su et al., 2015; Zhong et al., 2014) and patients affected by typical PCA syndrome (Whitwell et al., 2017) . Underlying CBD or DLB pathology in our PCA-nonAD cases is a potential cause of the group-specific frontal and mesio-temporal damage observed in this group in the present study. Finally, PCA-tAD also showed group-specific hypometabolism in the left inferior temporal gyrus, corresponding to the A C C E P T E D M A N U S C R I P T 26 more extensive temporal atrophy which is highly visible in this group (i.e. in the direct contrast between PCA-tAD and CTRL). This region is part of the so-called visual ventral stream which is typically impaired in PCA patients with AD pathology [(Migliaccio et al., 2012b) , also see occipito-temporal PCA in (Alladi et al., 2007) ]. This result is also consistent with previous imaging studies in PCA-AD patients showing decreased functional connectivity in the ventral stream (Migliaccio et al., 2016) . More generally, it seems to suggest a more widespread neurodegeneration in this PCA subtype.
The multimodal nature of our study highlights the importance of neuroimaging in both the diagnosis and characterization of PCA. In the present study, both MRI and PET results show a consistent epicenter of brain damage in PCA patients in bilateral parietal, occipital and posterior temporal regions. Nonetheless, our PET results revealed a more extended hypometabolism in associative regions in comparison to the GM atrophy pattern showed by our MRI results, although the PET analyses included a lower sample size.
This could suggest that PET is a more sensitive neuroimaging tool in comparison to MRI in the detection of brain damage in PCA patients. This is in accordance with the French guidelines, which recommend the use of PET in addition to morphological MRI to detect characteristic metabolism changes in posterior associative cortices in atypical presentations of AD (Haute Autorité de Santé (HAS), 2011). The clinical utility of PET was also highlighted in a previous meta-analysis in which it achieved the highest area under the receiver operating curve (0.96) for the diagnosis of AD, in comparison to CSF biomarkers and MRI GM atrophy, with a sensitivity of 90% and a specificity of 89% (Bloudek et al., 2011) . Furthermore, the present multimodal approach was able to detect subtle anatomo-functional differences among patients presenting with the same cognitive In terms of clinical profiles, all three PCA groups presented with typical visual and visuospatial impairments, irrespectively of their biological substrate (tAD, aAD or non-AD) and consistently with the common pattern of brain damage. and praxis functions were not extensively assessed, which could partially explain the lack of significant difference in the cognitive/clinical profiles across the PCA spectrum. In particular, memory and language were assessed for diagnosis purposes, but the data was not usable for research purposes (heterogeneity in assessment tools used, assessment conducted at different time points than the MRI, etc.). Finally, while our study is the first to investigate in vivo differences between PCA patients across the AD pathology spectrum, none of our subjects had post-mortem pathological diagnosis confirmation.
This study adds new insights to the limited literature investigating in vivo differences between PCA with diverse neuropathological substrates. On one hand, we can conclude that irrespectively of the underlying biological disease, the posterior brain regions are invariably impaired across the PCA spectrum. On the other hand, the underlying pathologies have an impact at least on the anatomical and metabolic brain patterns, because PCA-nonAD presented with an additional fronto-temporal (especially dorsolateral frontal) damage. The identification of three CSF profiles also should be taken in account: with the growing development of protein-specific therapies for AD, a better understanding of the impact of different underlying pathologies and profiles on the clinico-anatomical presentation is necessary. These results warrant the need for with the evolution of the disease, specifically in PCA-nonAD. Future studies should also study PCA patients using network-based or structural connectivity neuroimaging approaches, as their ability to discriminate other neurologic samples according to their underlying pathologies (Mahoney et al., 2014; Medaglia et al., 2017) . Highlights  In our sample, more than 80% PCA patients presented with an AD CSF profile.  In 20% PCA cases, CSF investigations suggested a non-AD pathology.  PCA-AD and PCA-nonAD patients were not clinically different on general measures.  All PCA patients presented the neurodegeneration profile commonly reported in PCA.  PCA-nonAD patients presented additional group-specific neurodegeneration in more anterior fronto-temporal regions.
